Tyzeka is a new oral antiviral for chronic hepatitis B

December 2006

Tyzeka is a new oral antiviral for chronic hepatitis B.

It's an alternative to using lamivudine (Epivir-HBV)...adefovir (Hepsera)...entecavir (Baraclude)...or interferons (Pegasys, etc).

Tyzeka (telbivudine) is well-tolerated like lamivudine...but it's more effective at suppressing the hepatitis B virus.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

50 million seniors age 60 and over to get Zostavax to prevent shingles
Cardiology risk of renal impairment in patients taking an ACE inhibitor or ARB, diuretic, and NSAID
Infectious Diseases new warnings of abnormal behavior and delirium in patients on Tamiflu (oseltamivir)
Infectious Diseases Tyzeka is a new oral antiviral for chronic hepatitis B
Risperdal is the first drug approved for use in autism
Muscle Relaxants differences between muscle relaxants
Patients are confused about all the new cough and cold products
Supplements evidence that DHEA (dehydroepiandrosterone) supplements don't slow aging
Supplements Tropical fruit juices such as MonaVie, XanGo, Noni, Goji, and Pom Wonderful are making a big splash
Women's Health what OTCs to use for GI problems during pregnancy
Adverse drug events send elderly patients to the emergency department
Smoking Cessation how Chantix compares to the older smoking cessation meds